Differences in exon expression and alternatively spliced genes in blood of multiple sclerosis compared to healthy control subjects

Yingfang Tian, Michelle L Apperson, Bradley Ander, Da Liu, Boryana S. Stomova, Glen C. Jickling, Richelle Enriquez, Mark A. Agius, Frank R Sharp

Research output: Contribution to journalArticle

12 Scopus citations


Using whole genome exon microarrays 120 exons were differentially expressed between medication-free multiple sclerosis (MS) subjects in remission and healthy control subjects (HS) (p < 0.001, fold change > |1.2|). These exons differentiated MS from HS using cluster analyses, principal components analyses (PCAs) and cross-validation. In addition, 340 genes (transcripts) were predicted to be alternatively spliced in MS compared to HS. These findings may provide insight into the pathophysiology of MS and potentially provide prognostic and diagnostic biomarkers. However, given that multiple comparisons were performed on a very small sample, these preliminary findings require confirmation using a much larger independent cohort.

Original languageEnglish (US)
Pages (from-to)124-129
Number of pages6
JournalJournal of Neuroimmunology
Issue number1-2
StatePublished - Jan 2011



  • Alternative splicing
  • Blood biomarker
  • Exon expression profiles
  • Gene expression profiling
  • Multiple sclerosis

ASJC Scopus subject areas

  • Immunology
  • Clinical Neurology
  • Immunology and Allergy
  • Neurology

Cite this